Results 91 to 100 of about 64,955 (112)

Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684

Journal of Clinical Oncology, 2023
PURPOSE Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following surgery for deep primary (T4) or regionally metastatic (N1) melanoma.
J. M. Kirkwood, M. H. Strawderman, M. Ernstoff, T. J. Smith, E. Borden, R. H. Blum   +5 more
semanticscholar   +1 more source

Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.

New England Journal of Medicine
BACKGROUND Once-weekly efanesoctocog alfa provides high sustained factor VIII activity with superior bleeding prevention as compared with prestudy factor VIII prophylaxis in previously treated patients 12 years of age or older with severe hemophilia A ...
L. Malec, F. Peyvandi, Anthony K C Chan, Christoph Königs, B. Zulfikar, Huixing Yuan, M. Simpson, M. Á. Álvarez Román, M. Carcao, J. Staber, Amy Dunn, Sheng-Chieh Chou, R. d'Oiron, M. Albisetti, M. Demissie, Elena Santagostino, A. Yarramaneni, Nancy Wong, Lydia Abad-Franch, S. Gunawardena, K. Fijnvandraat   +20 more
semanticscholar   +1 more source

Análisis de coste-efectividad de la administración de darbepoetina alfa una vez cada tres semanas frente a su administración semanal en el tratamiento de la anemia inducida por quimioterapia

, 2008
M. Riera, Ferrán Pérez, A. Vieta, R. Arocho   +3 more
semanticscholar   +1 more source

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

The Lancet Haematology, 2020
H. Gisslinger, C. Klade, P. Georgiev, D. Krochmalczyk, L. Gercheva‐Kyuchukova, M. Egyed, V. Rossiev, P. Dulíček, Á. Illés, H. Pylypenko, L. Sivcheva, J. Mayer, V. Yablokova, K. Krejcy, B. Grohmann-Izay, H. Hasselbalch, R. Kralovics, J. Kiladjian   +17 more
semanticscholar   +1 more source

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Lancet, The, 2007
Alain Ravaud, Sergio Bracarda, C?zary A Szczylik   +2 more
exaly  

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Lancet, The, 2005
Harry La Janssen, Yilmaz Cakaloglu, Guido Gerken   +2 more
exaly  

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Journal of Clinical Oncology, 2008
Brian I Rini, Susan Halabi
exaly  

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2014
Michael Manns, Maria Buti, Ewa Janczewska   +2 more
exaly  

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Lancet, The, 2008
Mario Santinami, Alessandro A E Testori, Reinhard Dummer   +2 more
exaly  

High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

Journal of Clinical Oncology, 2001
Joseph G Ibrahim, Vernon K Sondak
exaly